Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q2 FY26 results · Jul–Sep 2025
Panacea Biotec reported revenue from operations of ₹141.13 crore (down 4.2% from Q2 FY25) and net loss of ₹14.01 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 141.13 | 147.35 | −4.2% | 166.70 | −15.3% |
| Other income | 6.40 | 4.65 | +37.6% | 5.67 | +12.9% |
| Total income | 147.53 | 152.00 | −2.9% | 172.37 | −14.4% |
| Profit before tax | (19.17) | 4.76 | Turned loss | 6.56 | Turned loss |
| Net profit for the period | (14.01) | 4.71 | Turned loss | 3.96 | Turned loss |
| Attributable to shareholders of the company | (13.92) | 4.80 | Turned loss | 4.05 | Turned loss |
| EPS, basic (₹) | (2.27) | 0.77 | Turned loss | 0.66 | Turned loss |
| Net margin (%) | -9.9 | 3.2 | 2.4 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 90.81 | 76.64 | +18.5% | 112.25 | −19.1% |
| Other income | 3.61 | 3.41 | +5.9% | 4.95 | −27.1% |
| Total income | 94.42 | 80.05 | +18.0% | 117.20 | −19.4% |
| Profit before tax | (20.93) | 1.30 | Turned loss | (8.84) | Loss widened |
| Net profit for the period | (15.64) | 1.29 | Turned loss | (6.70) | Loss widened |
| EPS, basic (₹) | (2.55) | 0.21 | Turned loss | (1.09) | Loss widened |
| Net margin (%) | -17.2 | 1.7 | -6.0 |
Consolidated
- Filed with BSE
- 14 Nov 2025, 20:16 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2025, 20:16 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE